Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?

Novartis is teaming up with Allergan in a bid to get a treatment on the market for the fatty liver disease NASH, which currently has no approved treatments. The decision by Novartis to test its lead FXR agonist with Allergan's cenicriviroc (CVC) is interesting because Allergan's product reported mixed Phase II data.